Ariad Pharmaceuticals (ARIA): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Ariad Pharmaceuticals ( ARIA) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 1.2%. By the end of trading, Ariad Pharmaceuticals fell $0.30 (-4.3%) to $6.60 on light volume. Throughout the day, 15,148,516 shares of Ariad Pharmaceuticals exchanged hands as compared to its average daily volume of 25,913,600 shares. The stock ranged in price between $6.46-$6.95 after having opened the day at $6.94 as compared to the previous trading day's close of $6.90. Other companies within the Drugs industry that declined today were: Amarin Corporation ( AMRN), down 23.8%, Nanoviricides ( NNVC), down 17.5%, NovaBay Pharmaceuticals ( NBY), down 12.5% and Ocera Therapeutics ( OCRX), down 12.4%.

ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients. Ariad Pharmaceuticals has a market cap of $1.3 billion and is part of the health care sector. Shares are up 1.2% year to date as of the close of trading on Friday. Currently there are 3 analysts that rate Ariad Pharmaceuticals a buy, 3 analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Ariad Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, weak operating cash flow and generally disappointing historical performance in the stock itself.

On the positive front, ImmunoCellular Therapeutics ( IMUC), up 32.8%, Mast Therapeutics ( MSTX), up 29.6%, iBio ( IBIO), up 28.0% and Pacific Biosciences of California ( PACB), up 19.5% , were all gainers within the drugs industry with Gilead ( GILD) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

After Soaring to $150, Can Incyte Stir Up More Upside?

Biotech Buoyed by Deal Talk

The Next Target in Biotech Land

The Next Target in Biotech Land

Earnings Key to Next Week's Winners: Cramer's 'Mad Money' Recap (Friday 1/13/17)